On 23 April 2020, a presentation at the American Academy of Managed Care Pharmacy eLearning Days discussed future biosimilar launches in the US. A particular emphasis was placed on the number of adalimumab biosimilars waiting to come to market, with competition in this space expected to heat up in 2023. Possible biosimilar launches for 2020 which were discussed include pegfilgrastim, bevacizumab and rituximab.
Pearce IP BioBlast® for w/e 19 July 2024
19 July 2024 | EU | Gedeon Richter’s EU Denosumab Biosimilars AcceptedOn 19 July 2024, Gedeon Richter announced that the European Medicines Agency...